Carbidopa and Levodopa Carbidopa 25 MG Levodopa 100 MG Oral Tablet
INDICATIONS AND USAGE Carbidopa and levodopa tablets USP are indicated in the treatment of Parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets USP. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.
Teva Pharmaceuticals USA Inc
ROUND YELLOW Teva 93 293
Teva 93 293 ROUND YELLOW
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED Carbidopa and levodopa tablets USP, 10 mg/100 mg are available in the following form: Mottled-blue, round, scored tablets, debossed "93"-"292" on the scored side and plain on the other side, packaged in bottles of 100 (NDC 0093-0292-01) and 500 (NDC 0093-0292-05). Carbidopa and levodopa tablets USP, 25 mg/100 mg are available in the following form: Mottled-yellow, round, scored tablets, debossed "93"-"293" on the scored side and debossed "TEVA" on the other side, packaged in bottles of 100 (NDC 0093-0293-01), 500 (NDC 0093-0293-05) and 1000 (NDC 0093-0293-10). Carbidopa and levodopa tablets USP, 25 mg/250 mg are available in the following form: Mottled-blue, round, scored tablets, debossed "93"-"294" on the scored side and plain on the other side, packaged in bottles of 100 (NDC 0093-0294-01), 500 (NDC 0093-0294-05 ) and 1000 (NDC 0093-0294-10). Storage and Handling Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Store in a tightly closed container, protected from light and moisture. Dispense in a tightly closed, light-resistant container. Manufactured In Israel By: TEVA PHARMACEUTICAL IND. LTD. Jerusalem, 9777402, Israel Manufactured For: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454 Rev. U 9/2015
More pills like ROUND Teva 93 293